These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 34713519)
41. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728 [TBL] [Abstract][Full Text] [Related]
42. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY Oral Oncol; 2019 Aug; 95():95-99. PubMed ID: 31345401 [TBL] [Abstract][Full Text] [Related]
44. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Balermpas P; Bauer C; Fraunholz I; Ottinger A; Wagenblast J; Stöver T; Seitz O; Fokas E; Rödel C; Weiss C Strahlenther Onkol; 2014 Mar; 190(3):256-62. PubMed ID: 24413895 [TBL] [Abstract][Full Text] [Related]
45. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504 [TBL] [Abstract][Full Text] [Related]
46. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma. Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792 [TBL] [Abstract][Full Text] [Related]
47. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Strojan P; Vermorken JB; Beitler JJ; Saba NF; Haigentz M; Bossi P; Worden FP; Langendijk JA; Eisbruch A; Mendenhall WM; Lee AW; Harrison LB; Bradford CR; Smee R; Silver CE; Rinaldo A; Ferlito A Head Neck; 2016 Apr; 38 Suppl 1():E2151-8. PubMed ID: 25735803 [TBL] [Abstract][Full Text] [Related]
48. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970 [TBL] [Abstract][Full Text] [Related]
49. Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience. Karivedu V; Bonomi M; Issa M; Blakaj A; Klamer BG; Pan X; Old M; Bhateja P; Kang S; Seim N; Ozer E; Agrawal A; Mitchell D; Gamez ME; Grecula J; Jhawar SR; Baliga S; Carrau RL; Rocco J; Blakaj D Oncol Res Treat; 2021; 44(10):521-529. PubMed ID: 34515190 [TBL] [Abstract][Full Text] [Related]
50. Sarcopenia and its impact in head and neck cancer treatment. de Bree R; van Beers MA; Schaeffers AWMA Curr Opin Otolaryngol Head Neck Surg; 2022 Apr; 30(2):87-93. PubMed ID: 35255045 [TBL] [Abstract][Full Text] [Related]
51. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Mizumachi T; Homma A; Kakizaki T; Sakashita T; Kano S; Hatakeyama H; Tsuchiya K; Yasuda K; Onimaru R; Shirato H; Taguchi J; Shimizu Y; Kinoshita I; Akita H; Fukuda S Int J Clin Oncol; 2015 Jun; 20(3):431-7. PubMed ID: 24993675 [TBL] [Abstract][Full Text] [Related]
52. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084 [TBL] [Abstract][Full Text] [Related]
53. Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck. Loo SW; Geropantas K; Tasigiannopoulos Z; Martin C; Roques TW Eur J Cancer Care (Engl); 2013 Jan; 22(1):32-40. PubMed ID: 22519981 [TBL] [Abstract][Full Text] [Related]
54. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220 [TBL] [Abstract][Full Text] [Related]
55. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Papadimitrakopoulou VA; Frank SJ; Cohen EW; Hirsch FR; Myers JN; Heymach JV; Lin H; Tran HT; Chen CR; Jimeno A; Nedzi L; Vasselli JR; Lowe ES; Raben D Head Neck; 2016 Mar; 38(3):439-47. PubMed ID: 25352401 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. Strigari L; Pinnarò P; Carlini P; Torino F; Strolin S; Minosse S; Sanguineti G; Benassi M Crit Rev Oncol Hematol; 2016 Jun; 102():101-10. PubMed ID: 27157527 [TBL] [Abstract][Full Text] [Related]
58. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649 [TBL] [Abstract][Full Text] [Related]
59. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129 [TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]